Lisa Crocker

4.4k total citations · 2 hit papers
25 papers, 2.7k citations indexed

About

Lisa Crocker is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Lisa Crocker has authored 25 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Molecular Biology and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Lisa Crocker's work include HER2/EGFR in Cancer Research (14 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Lisa Crocker is often cited by papers focused on HER2/EGFR in Cancer Research (14 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Lisa Crocker collaborates with scholars based in United States, France and Australia. Lisa Crocker's co-authors include Mark X. Sliwkowski, Gail D. Lewis Phillips, Guangmin Li, Kathryn L. Parsons, Elaine Mai, Debra L. Dugger, Susan D. Spencer, Hartmut Koeppen, Ravi Chari and John M. Lambert and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Cancer Research.

In The Last Decade

Lisa Crocker

25 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

2008 1.3k citations Gail D. Lewis Phillips, Guangmin Li et al. Cancer Research profile →
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy

2008 501 citations Si Tuen Lee-Hoeflich, Lisa Crocker et al. Cancer Research profile →

Peers

Lisa Crocker

ONCOL

RNMI

PRM

IMMUN

Kathryn L. Parsons United States

Serengulam V. Govindan United States

Elaine Mai United States

Elicia Penuel United States

Thomas M. Cardillo United States

Guus A.M.S. van Dongen Netherlands

Márk Barok Finland

Jan Pinkas United States

Marie Prewett United States

Keng‐Hsueh Lan Taiwan

Kathryn L. Parsons United States

Lisa Crocker

2.1k ×1.0

ONCOL

1.8k ×1.1

RNMI

958 ×1.0

314 ×0.7

PRM

262 ×1.1

IMMUN

Citations per year, relative to Lisa Crocker Lisa Crocker (= 1×) peers Kathryn L. Parsons

Countries citing papers authored by Lisa Crocker

Since Specialization

Citations

This map shows the geographic impact of Lisa Crocker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Crocker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Crocker more than expected).

Fields of papers citing papers by Lisa Crocker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Crocker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Crocker. The network helps show where Lisa Crocker may publish in the future.

Co-authorship network of co-authors of Lisa Crocker

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Crocker. A scholar is included among the top collaborators of Lisa Crocker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Crocker. Lisa Crocker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yao, Xiaosai, Patrick Aouad, Lisa Crocker, et al.. (2025). ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer. Nature Cancer. 6(2). 357–371. 3 indexed citations

Chan, Jocelyn, Lily Shao, Scott Stawicki, et al.. (2022). Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action. Journal of Biological Chemistry. 299(1). 102729–102729. 1 indexed citations

Hegde, Ganapati V., Jennifer M. Giltnane, Lisa Crocker, et al.. (2019). NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma. eLife. 8. 9 indexed citations

Li, Guangmin, Jun Guo, Ben‐Quan Shen, et al.. (2018). Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells. Molecular Cancer Therapeutics. 17(7). 1441–1453. 141 indexed citations

Song, K S, Stephen Schmidt, Rebecca Hong, et al.. (2017). Abstract S6-04: The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action. Cancer Research. 77(4_Supplement). S6–4. 6 indexed citations

Asundi, Jyoti, Lisa Crocker, Jarrod R. Tremayne, et al.. (2015). An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. Clinical Cancer Research. 21(14). 3252–3262. 28 indexed citations

Wang, Weiru, Kristi Elkins, Angela Oh, et al.. (2014). Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors. PLoS ONE. 9(10). e109366–e109366. 30 indexed citations

Edgar, Kyle A., Lisa Crocker, Fang-You Chen, et al.. (2014). Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition. Genes & Cancer. 5(3-4). 113–126. 14 indexed citations

Phillips, Gail D. Lewis, Carter T. Fields, Guangmin Li, et al.. (2013). Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy. Clinical Cancer Research. 20(2). 456–468. 148 indexed citations

10.

Crocker, Lisa, Carter T. Fields, Lily Shao, et al.. (2012). Abstract 1212: The dual action antibody MEHD7945A targeting EGFR and HER3 enhances chemotherapy induced cytotoxicity in vitro and in vivo. Cancer Research. 72(8_Supplement). 1212–1212. 2 indexed citations

11.

Kamath, Amrita V., Dan Lu, Priyanka Gupta, et al.. (2011). Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemotherapy and Pharmacology. 69(4). 1063–1069. 32 indexed citations

12.

Junttila, Teemu T., Kathryn L. Parsons, Christine Olsson, et al.. (2010). Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer. Cancer Research. 70(11). 4481–4489. 179 indexed citations

13.

Jumbe, Nelson L. ‘Shasha’, Xin Yan, Douglas D. Leipold, et al.. (2010). Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. Journal of Pharmacokinetics and Pharmacodynamics. 37(3). 221–242. 90 indexed citations

14.

Kasman, Ian, Anil Bagri, Judy Mak, et al.. (2008). Mechanistic evaluation of the combination effect of anti-VEGF and chemotherapy. Cancer Research. 68. 2494–2494. 3 indexed citations

15.

Lee-Hoeflich, Si Tuen, Lisa Crocker, Evelyn Yao, et al.. (2008). A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy. Cancer Research. 68(14). 5878–5887. 501 indexed citations breakdown →

16.

Phillips, Gail D. Lewis, Guangmin Li, Debra L. Dugger, et al.. (2008). Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate. Cancer Research. 68(22). 9280–9290. 1259 indexed citations breakdown →

17.

Leipold, Douglas D., Nelson L. ‘Shasha’ Jumbe, Debra L. Dugger, et al.. (2007). Trastuzumab-MC-vc-PAB-MMAF: The effects of the Drug:Antibody Ratio (DAR) on efficacy, toxicity and pharmacokinetics.. Cancer Research. 67. 1551–1551. 3 indexed citations

18.

Crocker, Lisa, Gail D. Lewis Phillips, Brian Reardon, et al.. (2005). Evolution of the MDA-MB-175 breast cancer cell line from a low to a high HER2 expressing tumor line. Cancer Research. 65. 253–253. 1 indexed citations

19.

Tótpál, Klára, Mark X. Sliwkowski, Lisa Crocker, et al.. (2003). Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models. 44. 150. 20 indexed citations

20.

Verma, Paul J., Lisa Crocker, Renate Faast, et al.. (2000). In vitro development of porcine nuclear transfer embryos constructed using fetal fibroblasts. Molecular Reproduction and Development. 57(3). 262–269. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact